Overview

Bevacizumab for Neovascular Age-related Macular Degeneration

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
0
Participant gender:
All
Summary
Age-related macular degeneration (AMD) is one of primary blinding eye disease among people over 65 years in China. The anti-VEGF antibody treatment is proved useful for Neovascular Age-related Macular Degeneration (nAMD) by many studies. Bevacizumab is the only available low-cost type of anti-VEGF drug currently in China. This study is a multi-center, randomized trial of Bevacizumab effective dose and safety for nAMD. This study is to explore the effective therapeutic approach that the majority of patients in China can bear establishing a suitable treatment for China.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Peking University People's Hospital
Treatments:
Bevacizumab
Criteria
Inclusion Criteria:

- Clinical diagnosis of neovascular Age-related macular degeneration

- Signed informed consent

Exclusion Criteria:

- No other ocular fundus diseases